Tradestie Institutional Equity Comparison Engine

IRIX vs CPIX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CPIX Overall Edge

CPIX Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cumberland Pharmaceuticals Inc (CPIX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IRIX trades at N/M Forward P/E with -5.4% operating margin (-7.4% YoY revenue) versus CPIX at 50.0x Forward P/E and -4.7% operating margin (-74.0% YoY). In options structure, IRIX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CPIX sits in BREAKDOWN (37th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CPIX
IRIX N/M vs CPIX 50.0x Fwd P/E
Growth & Margin Winner CPIX
Op Margin -5.4% vs -4.7% ยท YoY -7.4% vs -74.0%
Momentum & Technical Winner CPIX
1Y -22.5% vs +149.3% ยท 52W Pos 8% vs 45%
Options & Structure Winner CPIX
UNCLASSIFIED (N/A IV) vs BREAKDOWN (37th %ile IV)
IRIX NASDAQ
Iridex Corp
Electromedical & Electrotherapeutic Apparatus
$0.69
-0.32% 1D
Market Cap $12.1M
1M Return -15.57%
1Y Return -22.49%
Forward P/E N/M
Unified AI Score
51.8 / 100 HOLD
Tech 52.0 Fund 65.0 Flow 50.0 Mom 50.0
CPIX NASDAQ
Cumberland Pharmaceuticals Inc
Pharmaceutical Preparations
$5.21
-11.39% 1D
Market Cap $88.2M
1M Return -27.44%
1Y Return +149.28%
Forward P/E 50.0x
Unified AI Score
49.1 / 100 HOLD
Tech 40.0 Fund 63.0 Flow 72.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IRIX -22.49% CPIX +149.28% Spread: +171.77 pp (CPIX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IRIX Revenue CPIX Revenue IRIX Op. Margin CPIX Op. Margin Margin Edge
FY2019 $40M $30M -20.7% -28.7% IRIX
FY2020 N/A $40M N/A -17.8% CPIX
FY2021 $40M $40M -18.1% -21.9% IRIX
FY2022 $60M $40M -13.2% -13.6% IRIX
FY2023 $50M $40M -19.3% -24.2% IRIX
FY2024 $50M $40M -17.1% -17.0% CPIX
FY2025 N/A $40M N/A -6.3% CPIX
FY2026 $50M N/A -4.9% N/A IRIX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IRIX (3) vs CPIX (7)
Institutional Metric IRIX CPIX Criterion Row Winner
Market Capitalization Scale $12.1M $88.2M Larger Scale CPIX
Trailing P/E Ratio Valuation N/M 50.0x Lower Multiple CPIX
Forward P/E Ratio Valuation N/M 50.0x Lower Multiple CPIX
Revenue Growth (YoY) Growth -7.4% -74.0% Higher Growth IRIX
Operating Margin (TTM) Profitability -5.4% -4.7% Higher Margin CPIX
Net Profit Margin Profitability -6.9% 148.6% Higher Margin CPIX
Return on Equity (ROE) Capital Efficiency -73.2% -3.4% Higher ROE CPIX
52-Week Range Position Momentum 8% ($1โ€“$2) 45% ($2โ€“$9) Stronger Trend CPIX
Beta / 30D Volatility Risk Regime 0.66ฮฒ ยท 58% Vol 0.44ฮฒ ยท 222% Vol Lower Realized Risk IRIX
Unified Institutional Score Composite Signal 51.8 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite IRIX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IRIX vs CPIX Buy Guide
IRIX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IRIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CPIX BREAKDOWN
87d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CPIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IRIX nor CPIX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.